PLX (Protalix BioTherapeutics) Future 3-5Y EPS without NRI Growth Rate: N/A (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLX Protalix BioTherapeutics Inc PLX
60 GF Score
Price $2.72
GF Value $2.20
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Protalix BioTherapeutics's Future 3-5Y EPS without NRI Growth Rate is N/A.

Protalix BioTherapeutics  (AMEX:PLX) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Protalix BioTherapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

PLX vs CUE, ORMP, ARMP: Future 3-5Y EPS without NRI Growth Rate Comparison

For the Biotechnology subindustry, Protalix BioTherapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protalix BioTherapeutics Future 3-5Y EPS without NRI Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.


PLX
60GF Score
Protalix BioTherapeutics Inc PLX
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Protalix BioTherapeutics (PLX) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of $2.72 is trading 23.6% above its estimated GF Value™ of $2.20. GuruFocus considers Protalix BioTherapeutics to be Modestly Overvalued.

Key valuation signals for PLX:

  • Future 3-5Y EPS without NRI Growth Rate: N/A
  • GF Value™: $2.20 vs. price of $2.72 (23.6% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protalix BioTherapeutics Business Description

Other Exchanges PBDA:Germany
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
60GF Score

Get the complete analysis for PLX

Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.72
Price
$2.20
GF Value